Side-by-side · Research reference

OvagenvsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

ATheoreticalHUMAN-REVIEWED2/42 cited

BPhase 3HUMAN-REVIEWED14/43 cited

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter

Ovagen

Sermorelin

Primary target

Ovarian tissue chromatin complexes

Pituitary GHRH receptorWalker 1994

Pathway

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Downstream effect

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Feedback intact?

Presumed physiological — Khavinson peptides described as regulatory, not replacement

Yes — short pulse preserves feedback

Origin

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

Antibody development

—

02Dosage Protocols

Parameter

Ovagen

Sermorelin

Standard dose

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

100–500 mcg per injectionMolteno 2013

Frequency

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Once daily, pre-sleep

Evidence basis

Theoretical / Russian-tradition

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Duration

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

8–12 weeks per cycle

Route

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

—

Lower / starter dose

—

100 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep, fasted preferred

Half-life

—

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

04Side Effects & Safety

Parameter

Ovagen

Sermorelin

Reported adverse events

None documented in indexed literature

—

Theoretical hormonal effects

Ovarian stimulation — monitor for estrogen-sensitive conditions

—

Injection site reaction

Possible mild erythema (SQ route)

Mild erythema, transient pain

Long-term safety

Unknown — no PubMed-indexed RCTs

—

Flushing / headache

—

Common transient effect

IGF-1 elevation

—

Modest at standard doses

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Glucose handling

—

Generally neutral

Absolute Contraindications

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

Sermorelin

·Untreated diabetes

05Administration Protocol

Parameter

Ovagen

Sermorelin

1. Oral route

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Subcutaneous route

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

SQ — abdomen or thigh. Rotate sites.

3. Cyclical protocol

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

Pre-sleep, fasted.

4. Storage

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Ovagen

— no documented stacks

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994